Lead compound 6c promotes specific survival and neuritogenesis of DA neurons, preserving DA transporter activity in two relevant in vitro models of PD, and does not influence cellular proliferation, thus representing a potential candidate for therapeutic applications in PD. This evidence concerns the gene SLC6A3 and Parkinson disease.